Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LKA651 in Diabetic Macular Edema
NCT02281292Phase 1Withdrawn
- Sponsor
- Alcon Inc.
- Start
- Dec 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of LKA651 in diabetic macular edema (DME) (4 arms), sponsored by Alcon Inc. Primary endpoints: Serious Adverse Events and Adverse Events. Planned start Dec 2015; status: withdrawn.
02
Drugs
LKA651
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02281292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281292.